» Articles » PMID: 21682755

Review Article: Faecal Transplantation Therapy for Gastrointestinal Disease

Overview
Date 2011 Jun 21
PMID 21682755
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Evidence is emerging regarding the relationship between a dysbiosis of the human gut microbiota and a number of gastrointestinal diseases as well as diseases beyond the gut. Probiotics have been investigated in many gastrointestinal disease states, with variable and often modest outcomes. Faecal transplantation is an alternative approach to manipulate the gut microbiota.

Aim: To review the use of faecal transplantation therapy for the management of gastrointestinal disorders.

Methods: Available articles on faecal transplantation in the management of gastrointestinal disorders were identified using a Pubmed search and bibliographies of review articles on the subject were collated.

Results: A total of 239 patients who had undergone faecal transplantation were reported. Seventeen of 22 studies of faecal transplantation were in fulminant or refractory Clostridium difficile. Studies of faecal transplantation are heterogeneous regarding the patients, donors, screening, methods of administration and definition of response. Faecal transplantation for C. difficile has been demonstrated to be effective in 145/166 (87%) patients. Small numbers of patients are reported to have undergone successful faecal transplantation for irritable bowel syndrome and inflammatory bowel disease.

Conclusions: Faecal transplantation has been reported with good outcomes for fulminant and refractory C. difficile. No adverse effects of faecal transplantation have been reported. However, there are no level 1 data of faecal transplantation and reports to date may suffer from reporting bias of positive outcomes and under-reporting of adverse effects. This therapy holds great promise, where a dysbiosis of the gut microbiota is responsible for disease and further studies are necessary to explore this potential.

Citing Articles

Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.

Jan N, Hays R, Oakland D, Kumar P, Ramakrishnan G, Behm B mSphere. 2021; 6(5):e0066921.

PMID: 34704776 PMC: 8550158. DOI: 10.1128/mSphere.00669-21.


Healthcare providers' perception of faecal microbiota transplantation with clostridium difficile infection and inflammatory bowel disease: a quantitative systematic review.

Liu Y, Alnababtah K, Cook S, Yu Y Therap Adv Gastroenterol. 2021; 14:17562848211042679.

PMID: 34567271 PMC: 8460966. DOI: 10.1177/17562848211042679.


Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?.

Zhou Y, Xu H, Huang H, Li Y, Chen H, He J Biomed Res Int. 2019; 2019:3469754.

PMID: 31467881 PMC: 6699279. DOI: 10.1155/2019/3469754.


Identification of the microbial diversity after fecal microbiota transplantation therapy for chronic intractable constipation using 16s rRNA amplicon sequencing.

Ohara T PLoS One. 2019; 14(3):e0214085.

PMID: 30889205 PMC: 6424423. DOI: 10.1371/journal.pone.0214085.


Fecal microbiota transplantation in recurrent infection: A retrospective single-center chart review.

Kim P, Gadani A, Abdul-Baki H, Mitre R, Mitre M JGH Open. 2019; 3(1):4-9.

PMID: 30834334 PMC: 6386733. DOI: 10.1002/jgh3.12093.